We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bionanomatrix Signs Cooperative Research and Development Agreement with NCI

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bionanomatrix Signs Cooperative Research and Development Agreement with NCI"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

BioNanomatrix LLC has announced that it has signed a multi-year Cooperative Research and Development Agreement (CRADA) with the Radiation Biology Branch at the National Cancer Institute (NCI) of the National Institutes of Health to develop methods to detect, identify and quantify DNA damage caused by ionizing radiation using BioNanomatrix’ whole genome analyzer, the NANOANALYZER™.

The BioNanomatrix NANOANALYZER is designed as an integrated system that can enable pan-genomic identification and analysis on a molecule-by-molecule basis, delivering single molecule sensitivity in a highly parallel format.

“Radiation therapy remains a mainstay of cancer treatment, but clinicians are hindered in their efforts to deliver an optimal dose by a lack of information on the extent of damage to the patient from the radiation already administered,” said Han Cao, Ph.D., chief scientific officer of BioNanomatrix.

“Under this CRADA, BioNanomatrix and NCI will collaborate to develop tools expected to dramatically improve monitoring and assessment of cancer therapies and therapeutic regimens, by allowing physicians to quantify easily and accurately the extent of DNA damage during treatment,” he said.

“This collaboration is an important step in the development of cancer diagnostics using the NANOANALYZER,” said Dr. Michael Boyce-Jacino, president and CEO of BioNanomatrix.

“This new agreement with the NCI will enable us to further develop our unique technology to support major advances in cancer diagnostics, systems biology and drug development and research,” said Dr Michael.

The CRADA is initially focused on employing the NANOANALYZER to assess radiation-induced damage to DNA. Pending results from these initial efforts, studies may also be performed to assess DNA damage and repair resulting from other cancer therapies, including chemotherapy.